Information Provided By:
Fly News Breaks for August 17, 2015
INCY
Aug 17, 2015 | 14:11 EDT
Cowen said an International Patent application filed by Incyte (INCY) and Merck (MRK) reveals early data from a Phase 1 trial on the on the combination of epacadostat, or IDO inhibitor, and Merck's anti-PD1 antibody. While preliminary, Cowen believes Incyte and Merck included data from the Phase I study in an effort to strengthen method of use claims around the combination and views anecdotal reports of activity as very encouraging. Incyte remains a top mid cap biotech pick at Cowen with an Outperform rating on shares .
News For INCY From the Last 2 Days
INCY
INCY
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.